European Stroke Organization Guidelines for the Management of Intracranial Aneurysms and Subarachnoid Haemorrhage

Cerebrovascular Diseases - Tập 35 Số 2 - Trang 93-112 - 2013
Kennedy R. Lees1, Seppo Juvela2, Andreas Unterberg3, Carla Jung3, Michael Forsting4, Gabriël J.E. Rinkel5
1Neurology and,
2Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland
3Neurosurgery, Heidelberg University, Heidelberg, and
4Department of Radiology, University of Essen, Essen, Germany
5Department Neurology, Utrecht University, Utrecht, The Netherlands

Tóm tắt

<b><i>Background:</i></b> Intracranial aneurysm with and without subarachnoid haemorrhage (SAH) is a relevant health problem: The overall incidence is about 9 per 100,000 with a wide range, in some countries up to 20 per 100,000. Mortality rate with conservative treatment within the first months is 50–60%. About one third of patients left with an untreated aneurysm will die from recurrent bleeding within 6 months after recovering from the first bleeding. The prognosis is further influenced by vasospasm, hydrocephalus, delayed ischaemic deficit and other complications. The aim of these guidelines is to provide comprehensive recommendations on the management of SAH with and without aneurysm as well as on unruptured intracranial aneurysm. <b><i>Methods:</i></b> We performed an extensive literature search from 1960 to 2011 using Medline and Embase. Members of the writing group met in person and by teleconferences to discuss recommendations. Search results were graded according to the criteria of the European Federation of Neurological Societies. Members of the Guidelines Committee of the European Stroke Organization reviewed the guidelines. <b><i>Results:</i></b> These guidelines provide evidence-based information on epidemiology, risk factors and prognosis of SAH and recommendations on diagnostic and therapeutic methods of both ruptured and unruptured intracranial aneurysms. Several risk factors of aneurysm growth and rupture have been identified. We provide recommendations on diagnostic work up, monitoring and general management (blood pressure, blood glucose, temperature, thromboprophylaxis, antiepileptic treatment, use of steroids). Specific therapeutic interventions consider timing of procedures, clipping and coiling. Complications such as hydrocephalus, vasospasm and delayed ischaemic deficit were covered. We also thought to add recommendations on SAH without aneurysm and on unruptured aneurysms. <b><i>Conclusion:</i></b> Ruptured intracranial aneurysm with a high rate of subsequent complications is a serious disease needing prompt treatment in centres having high quality of experience of treatment for these patients. These guidelines provide practical, evidence-based advice for the management of patients with intracranial aneurysm with or without rupture. Applying these measures can improve the prognosis of SAH.

Từ khóa


Tài liệu tham khảo

10.1161/STR.0b013e3182587839

10.1111/j.1468-1331.2004.00867.x

10.1097/00006123-199707000-00029

10.1161/STROKEAHA.107.498345

10.1136/jnnp.2007.117655

10.1161/01.STR.24.11.1649

10.1161/01.STR.29.1.251

10.1161/01.STR.27.9.1487

10.1161/01.STR.28.3.660

10.1097/00006123-200211000-00001

10.1212/WNL.30.10.1034

10.1002/ana.410040506

10.1001/archneur.1984.04050220036011

10.1161/01.STR.32.7.1499

10.1016/S1474-4422(09)70126-7

10.1136/bmj.304.6843.1663

10.1161/01.STR.0000080380.56799.DD

10.1136/jnnp.2007.123901

10.1159/000334660

10.1159/000338786

10.3171/jns.2005.102.6.0998

10.1212/01.WNL.0000090466.68866.02

10.1161/01.STR.0000221710.55467.33

10.1159/000317078

10.1161/01.STR.0000190838.02954.e8

10.1161/01.STR.0000014773.57733.3E

10.1161/01.STR.24.5.639

10.1161/01.STR.17.5.831

10.1161/01.STR.23.9.1242

10.1161/01.STR.32.5.1173

10.1161/01.STR.31.2.392

10.1016/S0140-6736(03)13860-3

10.1161/01.STR.32.2.485

10.1093/brain/awh587

10.1001/archneur.1995.00540260108026

10.1161/01.STR.29.2.359

10.1056/NEJM199209173271201

10.1161/01.STR.0000074572.91827.F4

10.1161/01.STR.27.1.7

10.1159/000111580

10.1212/WNL.53.5.982

10.1136/jnnp.62.3.273

10.1161/01.STR.27.4.630

10.1136/bmj.311.7000.288

10.1093/brain/awn187

10.1016/j.jocn.2004.07.021

10.1161/01.STR.32.5.1191

10.1212/01.wnl.0000304372.01248.02

10.1136/jnnp.58.3.357

10.1016/j.jvir.2009.01.012

10.1007/s00234-003-1155-1

10.3174/ajnr.A1884

10.1136/jnnp.2007.129189

10.1227/01.NEU.0000311064.18368.EA

10.1097/ANA.0b013e3180338e69

10.1161/STROKEAHA.107.509851

10.1056/NEJMoa040975

10.1016/0303-8467(90)90085-J

10.1186/cc2351

10.3171/jns.2005.102.2.0194

10.1097/00006123-199811000-00039

10.1002/14651858.CD001922.pub2

10.1212/01.wnl.0000176073.80532.a2

10.1212/WNL.55.9.1315

10.1212/01.wnl.0000281664.02615.6c

10.1097/00006123-200211000-00006

10.1385/NCC:4:2:103

10.1097/01.WNP.0000158361.24544.2D

10.1016/S0140-6736(05)67214-5

10.1136/jnnp.55.9.753

10.3171/JNS-07/08/0253

10.1002/14651858.CD004583.pub2

10.1161/STROKEAHA.106.480038

10.1161/01.STR.32.5.1176

10.1097/00006123-200202000-00018

10.1227/01.NEU.0000093199.74960.FF

10.3171/jns.2005.103.6.0982

10.1053/jscd.2002.130390

10.1016/S1474-4422(09)70080-8

10.1161/STROKEAHA.106.466987

10.3171/JNS/2008/108/3/0437

10.1016/j.clineuro.2007.09.022

10.3171/2009.9.JNS081645

10.1161/STROKEAHA.107.495747

10.1161/STROKEAHA.107.504670

10.1016/j.ejrad.2010.04.031

10.3171/2009.8.JNS081372

10.1161/STROKEAHA.107.506030

10.1002/14651858.CD001245

10.3171/jns.2002.97.4.0771

10.1136/jnnp.2009.182444

10.1161/01.STR.20.6.715

10.1002/ana.410310405

10.1212/WNL.42.9.1805

10.1097/00006123-199005000-00012

10.3171/jns.2005.103.3.0468

10.1385/NCC:5:3:193

10.1161/01.STR.0000251795.02560.62

10.1002/14651858.CD000277.pub3

10.1136/bmj.298.6674.636

10.1161/01.STR.0000254601.74596.0f

10.1038/jcbfm.2009.59

10.1161/STROKEAHA.109.556332

10.1136/jnnp.2006.104042

10.1016/S0140-6736(12)60724-7

10.1097/00006123-199905000-00097

10.1111/j.1552-6569.2006.00031.x

10.1016/0140-6736(91)91836-J

10.1016/S0140-6736(07)60153-6

10.1016/j.jstrokecerebrovasdis.2005.07.004

10.1148/radiol.2433060536

10.1007/s00234-007-0252-y

10.1161/01.STR.31.12.2976

10.1161/01.STR.30.5.1103

10.1016/S0150-9861(06)77236-4

10.1097/00006123-199609000-00001

10.1007/s12028-009-9203-2

10.1016/j.jocn.2008.10.008

10.1007/s12028-010-9354-1

10.1002/ana.410290503

10.1161/01.STR.0000260093.49693.7a

10.1161/01.STR.0000131657.08655.ce

10.1007/s002340050528

10.1111/j.1600-0404.1996.tb00011.x

10.1016/j.jocn.2005.09.007

10.1016/j.clineuro.2003.09.002

10.1056/NEJM199812103392401

10.1161/01.STR.29.8.1531

10.1016/S0140-6736(74)91639-0

Thông tin
Thông tin xuất bản

Cerebrovascular Diseases

Tập 35 Số 2

93-112

Thông tin tác giả